Nordic Life Science 1
first Robert Langer, co-founder, Moderna BUSINE S
S approved medicine in Japan to specifically reverse the anticoagulant effect of FXa inhibitors apixaban, rivaroxaban or edoxaban in patients experiencing a life-threatening or uncontrolled bleed. Japan is also the first country to provide full regulatory approval of Ondexxya for use with all three of the FXa inhibitors currently available. FXa inhibitors are increasingly used for the prevention and treatment of thrombotic events, including deep vein thrombosis and pulmonary embolism, or in patients at high risk of a stroke due to an irregular heart rate (atrial fibrillation). While they prevent unwanted clots from forming, they can also increase the risk of major bleeding, which can be life-threatening. AstraZeneca’s Maihara factory, Japan oderna plans to establish a commercial presence in Belgium, Denmark, Norway, the Netherlands, Poland, and Sweden to support the delivery of mRNA vaccines and therapeutics locally. In the European Union, the company’s COVID-19 vaccine and booster are approved for use by the European Commission for active immunization to prevent COVID-19 caused by the SARS-CoV-2 virus in individuals 18 years of age and older. To date, the European Commission has ordered 460 million doses of Moderna’s COVID-19 vaccine, including boosters and the ability to purchase other COVID-19 vaccine candidates from Moderna’s pipeline. The announcement reinforces Moderna’s commitment to Europe and vision as a global commercial enterprise, building on the recent announcement of expansion in the Asia-Pacific region, it states. PHOTO HEINZ TROLL PHOTO MODERNA